A new nanoparticle drug-delivery platform created by researchers at Queen's University Belfast may be able to target and effectively treat severe lung trauma in patients in intensive care.
Texas biotech Mirna Therapeutics began a Phase I clinical trial of its miRNA cancer drug MRX34 with a liposomal delivery platform the company licensed from Marina Biotech. It is the first miRNA drug to advance to the clinic for cancer.
A new delivery platform called chain-shattering polymers developed by researchers at the University of Illinois could hold the key to the more controlled release of drugs at localized sites and tissues.
A team of researchers at Tel Aviv University has developed a biodegradable implant that delivers a gel capable of restoring healthy nerve function to treat diseases such as Parkinson's.
Merck won the FDA's acceptance of a Biologics License Application for its investigational ragweed pollen allergy tablet to be delivered under the tongue.
In another step toward realizing the elusive potential of RNA drugs, scientists at the Scripps Research Institute have nailed down one of the mechanisms by which the gene-silencers reach their targets in the cell's nucleus.
Researchers at the Frederick National Laboratory for Cancer Research have developed a way to enhance delivery of a cancer drug using nanoparticles, enabling more of the toxic therapy to reach the tumor without killing healthy cells.
With an increasing reliance on nanoparticles to deliver intravenous drug treatments and serve as imaging agents, how do you make sure they are powerful enough to reach their target? The answer: math.
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
Using a soccer-ball-shaped nanoparticle named after famed inventor Buckminster Fuller, researchers at Columbia Engineering have created a drug-delivery capsule with precise targeting capabilities.
Researchers from several U.S. institutions have created a 'smart' nanoparticle for insulin delivery that reacts to changes in blood chemistry and releases the protein when needed.
Insulet, creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly this week to develop a new version of the device designed to deliver Lilly's Humulin R U-500 insulin.
Researchers at the Karolinska Institute are studying the transport proteins on tumor cell membranes that allow nutrients into the cell. By exploiting these proteins, they hope to be able to fight cancer cells by starving them, and learn more about the delivery of drugs to those cells.
This week, Tocagen began enrolling patients in a Phase I trial in which its Toca 511 cancer drug is delivered using a visually guided device called ClearPoint, the first such device of its kind, that allows for a more concentrated delivery, increasing the drug's effectiveness as much as threefold.
Pharmaco-Kinesis Corporation has combined two tested, on-the-market cancer drugs to form one super-drug. If successful, it will be the first combination nano-drug product candidate.
Researchers at Harvard and Boston University have developed a surgical technique to surmount one of the trickiest of drug-delivery obstacles--the blood-brain barrier.
Delcath Systems' cancer-drug delivery device suffered a hitch as the FDA said the associated risks likely outweigh any benefit.
German researchers are using the highly stable structure of a uniquely shaped human immune protein as a model for high-concentration vaccine delivery.
Because of InsuPatch's mechanism of delivery, the company must submit an IND on top of its previous 510(k) de novo application.
Researchers at the University of Rochester Medical Center have developed a way to make a well-known breast cancer drug more effective against aggressive forms of the disease by altering slightly the treatment's target mechanism.